Altamira Therapeutics Announces Publication of Positive Results from Phase 2 Trial with AM-125 in Acute Vestibular Syndrome in Leading Peer Reviewed Journal
- Detailed results from TRAVERS trial addressing acute vestibular syndrome with AM-125 (intranasal betahistine) published in Otology & Neurotology
- Study demonstrates proof of concept and shows good tolerability
- TRAVERS shows time and dose dependent acceleration of vestibular compensation and alleviation of signs and symptoms of vestibular dysfunction
- Altamira intends to partner or divest AM-125, part of its legacy assets, in a strategic pivot to RNA delivery technology